

International Journal of Molecular Medicine

ISSN 1107-3756
eISSN 1791-244X

VOLUME 44, SUPPLEMENT 1, 2019



**Proceedings of the Abstracts of
The 24th World Congress on Advances in Oncology,
and
24th International Symposium on Molecular Medicine**

**10-12 October, 2019, Mystras Grand Palace Resort,
Sparta, Greece**

International Journal of Molecular Medicine

ISSN 1107-3756
eISSN 1791-244X

Editor in Chief

DEMETRIOS A. SPANDIDOS, BSc, PhD, FRCPath, DSc, FRSH, FASA
Professor Emeritus, Medical School, University of Crete, Heraklion, Greece
Spandidos Publications, Greece

Deputy Editors

ATHANASIA SPANDIDOS, BSc (Hons), PhD
Faculty Member, Department of Biomedical Sciences, University of Greenwich, Athens, Greece
Spandidos Publications, Greece

NIKIFOROS A. SPANDIDOS, BSc (Hons), MSc, PhD
Spandidos Publications, United Kingdom

Fax: +30 210 725 2922; Tel: +30 210 722 7809
e-mail: contact@spandidos-publications.com
Web-site: www.spandidos-publications.com

Submission of manuscripts

Online: www.spandidos-publications.com

By courier service/overnight mail: Professor D.A. Spandidos,
Editorial Office: 10, Vriaxidos Street, Athens 116 35, Greece

Aims and scope: *International Journal of Molecular Medicine* is a journal providing rapid publication in the field of molecular and clinical research on the mechanisms of diseases related to man, including biology, biochemistry, physiology, immunology, pharmacology, pathology, gene therapy, genetics, virology, hematology, endocrinology, microbiology, oncology, epidemiology, neurosciences, infectious diseases, molecular pathogenesis, human genomics, molecular cardiology, molecular surgery, molecular psychology. Studies *in vitro* or *in vivo* on experimental model systems relevant to the mechanisms of disease are also considered. All manuscripts submitted to the *International Journal of Molecular Medicine* are subject to review.

Publication data: *International Journal of Molecular Medicine* is published monthly.

Annual subscription rates: Print and online subscription rates available at contact@spandidos-publications.com

Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by the *International Journal of Molecular Medicine*, provided that the base fee of US\$32.00 per copy, plus 0.40 per page is paid directly to Copyright Clearance Center, 27 Congress Street, Salem, MA 01970, USA. For those organizations that have been granted a photocopy licence by CCC, a separate system of payment has been arranged. The fee code for users of the Transactional Reporting Service is 1019-6439/93 US\$32.00 + 0.40.

Editorial board:

The Editorial Board of the *International Journal of Molecular Medicine* consists of experts in their field who are members of The Editorial Academy of the *International Journal of Molecular Medicine*.

Editorial Academy of the International Journal of Molecular Medicine:

To qualify as a member of The Editorial Academy each editor must have 1000 citations of his work as first author or over 2000 in total or over 100 publications in refereed journals and to have contributed significantly to molecular medicine. To apply to become a member of The Editorial Academy you should submit your CV to the Editorial Office.

Bibliographic services: Articles in the *International Journal of Molecular Medicine* are listed in bibliographic services including Current Contents/Life Sciences, Index Medicus, MEDLINE, PubMed Central, Science Citation Index, Biochemistry & Biophysics Citation Index, Science Citation Index Expanded (SciSearch), ISI Web of Science, Chemical Abstracts, BIOSIS and Index Copernicus.

The Editors and Publishers of *International Journal of Molecular Medicine* accept no responsibility for the opinions expressed by the contributors appearing herein.

Copyright: Once the manuscript has been published the legal ownership of all published parts of the paper has passed from the Author(s) to the journal.

International Journal of Molecular Medicine

ISSN 1107-3756
eISSN 1791-244X

Editorial Board

- **ALFRED L.M. BOTHWELL**
Yale University School of Medicine, USA
- **BRENDAN F. BOYCE**
University of Rochester Medical Center, USA
- **GIOVANNI CAMUSSI**
University of Turin, Italy
- **GEORGE CHACONAS**
University of Calgary, Canada
- **JEROLD CHUN**
Sanford Burnham Prebys Medical Discovery Institute, USA
- **LUCIO I.M. COCCO**
University of Bologna, Italy
- **MAX D. COOPER**
Emory University School of Medicine, USA
- **RONALD W. DAVIS**
Stanford Genome Technology Center, USA
- **TED M. DAWSON**
Johns Hopkins University School of Medicine, USA
- **MICHELE DE LUCA**
University of Modena and Reggio Emilia, Italy
- **PIERRE DESREUMAUX**
Lille Hospital, Huriez Hospital, France
- **RONALD C. DESROSIERS**
Harvard Medical School, USA
- **E.T. DETORAKIS**
University of Crete, Greece
- **KARL DRLICA**
New Jersey Medical School, Rutgers, USA
- **DENIS DUBOULE**
University of Geneva, Switzerland
- **IAN D. DUNCAN**
University of Wisconsin-Madison, USA
- **MARK J. DUNNE**
University of Manchester, UK
- **TOMAS J. EKSTRÖM**
Karolinska Institutet, Sweden
- **JACK A. ELIAS**
Brown University, USA
- **MAGDY EL-SALHY**
Stord Helse-Fonna Hospital, Norway
- **JONAS NYGAARD ERIKSEN**
Aarhus University, Denmark
- **DAVID FELDMAN**
Stanford University School of Medicine, USA
- **VICENTE FELIPO**
Prince Felipe Research Center, Spain
- **GARY S. FIRESTEIN**
University of California, USA
- **DAVID C. FISHER**
Dana-Farber Cancer Institute, USA
- **GERHARD FRITZ**
Heinrich Heine University Düsseldorf, Germany
- **AKIYOSHI FUKAMIZU**
University of Tsukuba, Japan
- **ARNOLD GANSER**
Hannover Medical School, Germany
- **WILLIAM A. GODDARD III**
Materials and Process Simulation Center, USA
- **JOHN GROFFEN**
University of Southern California, USA
- **H. HONDA**
Yokohama Rehabilitation Center, Japan
- **RANDALL E. HARRIS**
The Ohio State University, USA
- **BARTON FORD HAYNES**
Duke University School of Medicine, USA
- **NORA C. HEISTERKAMP**
Beckman Research Institute City of Hope, USA
- **JOHAN HOEBEKE**
Institute of Molecular and Cell Biology (IBMC), France
- **TAKAHIKO HORIUCHI**
Kyushu University Beppu Hospital, Japan
- **TOMAS HÖKFELT**
Karolinska Institutet, Sweden
- **MITSUO IKEBE**
University of Massachusetts Medical School, USA
- **WEN GUO JIANG**
Cardiff University School of Medicine, UK
- **LEVON MICHAEL KHACHIGIAN**
University of New South Wales, Australia
- **HIROSHI KIJIMA**
Hirosaki University Graduate School of Medicine, Japan
- **KEE-HONG KIM**
Purdue University, USA
- **NAM DEUK KIM**
Pusan National University, Republic of Korea
- **DENNIS M. KLINMAN**
NIH Center for Cancer Research, USA
- **MALAK KOTB**
University of North Dakota, USA
- **CATHARINA LARSSON**
Karolinska University Hospital Solna, Sweden
- **NORBERT LATRUFFE**
University of Burgundy, France
- **ROBERT A. LEVINE**
Massachusetts General Hospital, USA
- **CHARLES LIEBOW**
University of Connecticut Health Center, USA
- **YOUHUA LIU**
University of Pittsburgh, USA
- **YOKE PENG LOH**
Eunice Kennedy Shriver Nat. Inst. of Child Health & Human Develop., USA
- **JOSEPH LOSCALZO**
Brigham and Women's Hospital, USA
- **TIMOTHY J. MCDONNELL**
University of Texas MD Anderson Cancer Center, USA
- **KENNETH MAIESE**
UMDNJ-New Jersey Medical School, USA
- **WILLY J. MALAISSE**
Brussels Free University, Belgium
- **LUDWIK KAZIMIERZ MALENDOWICZ**
Poznan University of Medical Sciences, Poland
- **DARIO MARCHETTI**
Houston Methodist Research Institute, USA
- **CARLOS MARTÍNEZ-A**
National Center for Biotechnology (CNB-CSIC), Spain
- **JEAN MARTINEZ**
University of Montpellier, France
- **YOSHINORI MARUNAKA**
Kyoto Prefectural University of Medicine, Japan
- **IAN W. MATTAJ**
European Molecular Biology Laboratory (EMBL) Heidelberg, Germany
- **MAKOTO MAYUMI**
Jichi Medical School, Japan
- **LAURENCE J. MILLER**
Mayo Graduate School of Medicine, USA

- **TAKASHI MINEGISHI**
Gunma University Graduate School of Medicine, Japan
- **JAMES I. MORGAN**
St. Jude Children's Research Hospital, USA
- **MASAYOSHI NAMBA**
Okayama University Medical School, Japan
- **MARKUS F. NEURATH**
Friedrich-Alexander University, Germany
- **RACHAEL L. NEVE**
McGovern Institute for Brain Research at MIT, USA
- **FERDINANDO ROSARIO NICOLETTI**
University of Catania, Italy
- **GUNILLA OLIVECRONA**
Umeå University, Sweden
- **PAL PACHER**
National Institute on Alcohol Abuse and Alcoholism, USA
- **VASSILIOS PAPADOPOULOS**
University of Southern California, USA
- **KLAUS PFIZENMAIER**
University Hospital Regensburg, Germany
- **MICHAEL POLLAK**
McGill University, Canada
- **WILLIAM A. PRYOR**
Louisiana State University, USA
- **KATYA RAVID**
Boston University School of Medicine, USA
- **MARTIN C. RECHSTEINER**
University of Utah School of Medicine, USA
- **HORACIO RICO**
University of Alcalá, Spain
- **SIMON C. ROBSON**
Harvard Medical School, USA
- **JACK A. ROTH**
University of Texas MD Anderson Cancer Center, USA
- **IKUO SAIKI**
University of Toyama, Japan
- **GAETANO SANTULLI**
Montefiore University Hospital, USA
- **ANDREW V. SCHALLY**
University of Miami, USA
- **CLAUS SCHEIDEREIT**
Max Delbrück Center for Molecular Medicine (MDC), Germany
- **STUART FRANKLIN SCHLOSSMAN**
Dana Farber Cancer Institute, USA
- **AVITAL SCHURR**
University of Louisville, School of Medicine, USA
- **TERRENCE J. SEJNOWSKI**
The Salk Institute for Biological Sciences, USA
- **TSUKASA SEYA**
Hokkaido University Graduate School of Medicine, Japan
- **JERRY W. SHAY**
University of Texas Southwestern Medical Center, USA
- **CHANGSHUN SHAO**
Soochow University, P.R. China
- **YUN-BO SHI**
Eunice Kennedy Shriver NICHD, US National Institutes of Health, USA
- **KAI SIMONS**
Max Planck Institute of Molecular Cell Biology and Genetics, Germany
- **GEORGE B. STEFANO**
First Faculty of Medicine, Charles University, Czech Republic
- **WALTER J. STORKUS**
University of Pittsburgh School of Medicine, USA
- **ANDREAS STRASSER**
Walter and Elizer Hall Institute of Medical Research, Australia
- **ROBERT M. STRIETER**
University of Virginia School of Medicine, USA
- **CSABA SZABO**
University of Texas Medical Branch, USA
- **HIROSHI TAKAYANAGI**
University of Tokyo, Japan
- **LEON F. TSENG**
Medical College of Wisconsin, USA
- **ARTHUR VEIS**
Northwestern University, USA
- **FENG-SHENG WANG**
Kaohsiung Chang Gung Memorial Hospital, Taiwan, R.O.C.
- **PING WANG**
The Feinstein Institute for Medical Research, USA
- **GERALD N. WOGAN**
Massachusetts Institute of Technology, USA
- **CHARLES E. WOOD**
University of Florida College of Medicine, USA
- **YOSHIJI YAMADA**
Mie University, Japan
- **MASAYOSHI YAMAGUCHI**
University of Hawaii at Manoa, USA
- **DAZHONG YIN**
Hunan Normal University, P.R. China
- **ROLF MARTIN ZINKERNAGEL**
University of Zurich, Switzerland

173

Sirolimus-mediated induction of fetal hemoglobin in beta-thalassemia: Impact of the Xmn1 rs74482144 polymorphismCristina Zuccato¹, Lucia Carmela Cosenza¹, Giulia Breveglieri¹, Chiara Gemmo¹, Iaria Lampronti¹, Enrica Fabbri¹, Nicoletta Bianchi¹, Monica Borgatti¹, Jessica Gasparello¹, Alessia Finotti¹, Marco Prodocimi², Roberto Gambari¹¹Department of Life Sciences and Biotechnology, Ferrara University, Ferrara, Italy; ²Rare-Partners Srl, Milano, Italy
E-mail: gam@unife.it

The *in vivo* effects of sirolimus on the induction of fetal hemoglobin (HbF) is of key importance for therapeutic protocols in a variety of hemoglobinopathies, including β -thalassemia and sickle-cell disease (SCD). We have previously reported the strong inducing effect of the mTOR inhibitors rapamycin (sirolimus) and everolimus on HbF production by erythroid precursors (ErPCs) from β -thalassemia patients. We took advantage from the availability of a β -thalassemia cellular bio-bank allowing stratification of the patients with respect to fetal hemoglobin production and response to HbF inducers. The results obtained by HPLC analysis of the ErPCs cultures from 38 patients led to the following conclusions: (a) sirolimus increases HbF in cultures from β -thalassemia patients with different basal HbF levels (the cultures from 51.4% of the patients were responsive to sirolimus treatment); (b) the cultures from 37.8% of the patients were not responsive to sirolimus or hydroxyurea (HU); (c) sirolimus was able to induce HbF in 46.15% of the cultures not responsive to HU; (d) sirolimus displayed higher efficiency than HU in 57.14% of the cultures responsive to both sirolimus and HU; (e) 42.86% of HU-treated cultures displayed HbF induction higher than sirolimus. In order to study a possible association between DNA polymorphisms and sirolimus-mediated HbF induction, the γ -globin Xmn1 (rs74482144), two BCL11A (rs1427407 and rs10189857) and the HS1L-cMYB rs9399137 polymorphisms were analyzed. Both homozygous Xmn1 (T/T,+/+) and heterozygous Xmn1 (T/C,+/-) cultures (from 11 patients, 29.9% of the 38 patients analyzed) had high sirolimus-mediated HbF induction. The BCL11A rs1427407 G>T polymorphism was not associated with high HbF induction. Concerning the HS1L-cMYB T>C rs9399137 and the BCL11A A>G rs10189857 polymorphisms, an association with sirolimus-mediated HbF induction was found, but only in the homozygous patients (3/38 and 7/38, respectively). These results indicate that the γ -globin Xmn1 rs74482144 should be considered a very useful polymorphism for recruitment of β -thalassemia patients in sirolimus-based clinical trials.

Acknowledgements: UE FP7 THALAMOSS Project (grant no. 306201-FP7-Health-2012-INNOVATION-1), by Wellcome Trust and by AIFA (Agenzia Italiana del Farmaco).

174

Non-invasive prenatal detection of beta-thalassemia mutations in maternal plasma using Droplet Digital PCRElisabetta D'Aversa¹, Giulia Breveglieri¹, Patrizia Pellegatti², Giovanni Guerra², Roberto Gambari¹, Monica Borgatti¹¹Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy; ²Operative Unit of Laboratory Analysis, University Hospital S. Anna, Ferrara, Italy
E-mail: monica.borgatti@unife.it, gam@unife.it

Non-invasive prenatal testing (NIPT) is based on fetal DNA analysis with the aim to identify genetic abnormalities from the maternal plasma during pregnancy⁽¹⁾. Actually, commercial NIPT kits can detect only aneuploidies, small deletions or insertions but not single point mutations causing genetic diseases. In this study, we have developed two genotyping assays, based on innovative and sensitive droplet digital PCR (ddPCR) technology⁽²⁾ to identify the two most common thalassemia mutations in the Mediterranean population (β^0 39 and β^0 IVSI-110) maternally and/or paternally inherited on fetal DNA. First, the two genotyping assays were optimized and validated, in terms of amplification efficiency and hybridization specificity, using mixtures of two genomic DNAs carrying different genotypes and percentages to simulate fetal and maternal circulating cell-free DNA (cfDNA) at different gestational weeks. Then the two ddPCR assays were applied to determine the fetal genotype from 36 maternal blood samples at different gestational ages. The diagnostic outcomes were confirmed for all the samples carrying paternally inherited mutation by DNA sequencing. In the case of maternally or both parents inheriting the mutation a precise dosage of normal and mutated alleles was required to determine the fetal genotype. In particular, we identified two diagnostic ranges for allelic ratio values that were statistically distinct and not overlapping, allowing the corrected fetal genotype determination in all the samples analyzed. In conclusion, we have developed a simple and sensitive diagnostic approach, based on ddPCR, for non-invasive pre-natal determination of β^0 IVSI-110 and β^0 39 mutations paternally and maternally inherited suggesting its application also for other single point mutations causing monogenic diseases.

Acknowledgements: This work was supported by the Italian Ministry of Health under the project no. 098/GR-2009-1596647-Young Investigators-2009 and FIR 2017-University of Ferrara to MB. The QX200™ Droplet Digital™ PCR system (Bio-Rad Laboratories, Hercules, CA, USA) was funded by Ferrara University Grant 'Bando per l'acquisizione di strumenti per la ricerca di ateneo-2015'.

- (1) Breveglieri G, et al. Mol Diagn Ther 23: 291-299, 2019.
(2) D'Aversa E, et al. Mol Med 24: 14, 2018.

175

Identification of dysregulated miRNAs in liquid biopsies from colorectal cancer (CRC) patients: Impact on personalized miRNA therapeutics

Alessia Finotti, Roberto Gambari

Department of Life Sciences and Biotechnology, University of Ferrara, Ferrara, Italy
E-mail: alessia.finotti@unife.it

MicroRNAs (miRNAs) are small non-coding RNAs regulating gene expression by the sequence-selective targeting of mRNAs, leading to translational repression or mRNA degradation. In cancer, miRNAs are associated with tumor onset and progression. Liquid biopsy of cancer is based on the analysis of circulating tumor cells and/or cell-free nucleic acids (including miRNAs) in peripheral blood of cancer patients and it is considered one of the most advanced non-invasive diagnostic systems suitable for early diagnosis, staging, prognosis, prediction of therapy responses, therapy outcome, and follow-up during therapeutic intervention (1). We performed NGS of plasma isolated from 35 colorectal carcinoma (CRC) patients and identified a short-list of 12 dysregulated miRNAs, including miR-221, miR-222 and miR-141. These data were further validated by droplet digital RT-PCR (dd-RT-PCR). Despite the fact that patient-to-patient heterogeneity was found, this study provides a list of novel potential targets for the development of therapeutic protocols for CRC. The association between the miRNAs expressed in tumors and their plasma content was validated in experimental mice xenografted with tumor cell lines derived from CRC patients (2). For miRNA targeting, peptide-nucleic acids (PNAs), DNA analogues in which the sugar-phosphate backbone has been replaced by N-(2-aminoethyl)glycine units, are excellent tools. We developed novel delivery strategies for PNAs targeting miRNAs, based on i) the use of PNAs linked to a poly-arginine R8 peptide tail; ii) nanoparticles; and iii) novel molecules constituted by a macrocyclic multivalent tetraargininocalix[4]arene to be used as non-covalent vector for anti-miRNA PNAs (3). As far as the validation of PNA activity, we focused on PNAs targeting miR-221, miR-222 and miR-155 in glioblastoma cells. Increased pro-apoptotic effects were obtained with the co-administration of these PNAs. In addition, synergistic effects were found with the co-administration of corilagin and a PNA targeting miR-221. Finally, the combined treatment of glioma U251 cells with the pro-apoptotic pre-miR-124 and the PNA targeting miR-221, led to the induction of apoptosis at very high levels. In conclusion, the liquid biopsy approach may be considered the basis for a personalized miRNA based therapy of cancer, and PNAs may be a relevant therapeutic tool for the inhibition of oncomiRNAs, also in combination with miRNA replacement molecules mimicking tumor-suppressor miRNAs.

Acknowledgements: This study was funded by AIRC IG13575, and FAR fund from University of Ferrara.

- (1) Finotti A, et al., Int J Oncol 53(4): 1395-1434, 2018;
(2) Gasparello J, et al., J Exp Clin Cancer Res 37: 124, 2018;
(3) Gasparello J, et al., Sci Rep 9: 3036, 2019.

176

Downregulation of LYAR is associated with induction of fetal hemoglobin in mithramycin-treated erythroid cells

Lucia Carmela Cosenza, Jessica Gasparello, Matteo Zurlò, Cristina Zuccato, Roberto Gambari, Alessia Finotti

Department of Life Sciences and Biotechnology, Ferrara University, Ferrara, Italy
E-mail: alessia.finotti@unife.it

LYAR (Ly-1 antibody reactive clone) protein is a recently identified repressor of γ -globin gene transcription in erythroid cells and binds to the 5'-GGTTAT-3' sequence of the 5'-region of the gene. The rs368698783 G>A polymorphism of this site is present in β -thalassemia patients and is associated with a high production of fetal hemoglobin (HbF). The finding that LYAR binds less efficiently to the G>A mutated 5'-GGTTAT-3' binding site might explain the increased basal and induced levels of HbF in erythroid cells. The present study was undertaken to verify the effects of the HbF inducer mithramycin (MTH) on LYAR. We first determined whether MTH was able to inhibit the LYAR/DNA interactions using both nuclear factors from K562 cells and recombinant LYAR protein. Electrophoretic mobility shift assay demonstrated that MTH strongly interfered with the binding of LYAR to the double-stranded oligonucleotides containing the γ -globin LYAR binding site. We also performed RT-qPCR and western blot analysis of MTH-treated cells demonstrating an association between LYAR mRNA and γ -globin gene expression. LYAR expression (analyzed at mRNA and at the protein level) was downregulated in association with the upregulation of γ -globin gene expression and HbF production. LYAR downregulation was confirmed in MTH-treated K562 cells, as well as in erythroid precursor cells (ErPCs) from β -thalassemia patients. In the analyzed ErPCs those which were found as non-responders to MTH demonstrated unchanged LYAR content. In order to verify possible MTH-dependent effects on LYAR transcription, the LYAR promoter was studied and at least five Sp1 CG-rich binding sites identified. EMSA was performed using double-stranded oligonucleotides mimicking these binding sites and the effects of MTH addition were determined, demonstrating that MTH is able to inhibit the interactions between Sp1 and the Sp1 binding sites present within the LYAR promoter. In conclusion, downregulation of LYAR expression and functions might strongly contribute to induction of γ -globin gene expression and HbF production in erythroid cells.

Acknowledgements: Supported by the UE FP7 THALAMOSS Project (THALAssaemia Modular Stratification System for personalized therapy of beta-thalassemia; grant n.306201-FP7-Health-2012-INNOVATION-1), by Wellcome Trust and by AIFA (Agenzia Italiana del Farmaco).